Biohaven Ltd. (BHVN) Q1 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2025. Biohaven Ltd. is a biopharmaceutical company focused on the discovery, development, and commercialization of treatments in immunology, neuroscience, and oncology. The company operates as a single segment and has not yet generated revenue from product sales. As of May 9, 2025, there were 102,112,524 common shares outstanding.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(221.7) million | $(179.5) million |
| Net Loss Per Share (Basic & Diluted) | $(2.17) | $(2.20) |
| Operating Expenses | $221.6 million | $183.2 million |
| Cash and Cash Equivalents | $98.4 million | $182.7 million |
| Marketable Securities | $224.3 million | $312.3 million |
| Total Liquidity (Cash + Securities) | $322.7 million | $495.0 million |
| Net Cash Used in Operating Activities | $(165.1) million | $(102.6) million |
| Debt | None reported on balance sheet (See Subsequent Events) | None |
Material Changes vs. Prior Period
- Increased Net Loss: Net loss increased by $42.2 million (23.5%) year-over-year, driven primarily by higher Research and Development (R&D) expenses.
- R&D Expense Growth: R&D expenses rose to $187.6 million from $156.0 million. This increase was due to higher non-cash share-based compensation ($35.2 million vs. $21.3 million) and increased direct program spend for clinical trials and preclinical research. Specific increases were noted in the BHV-7000 (Kv7) and BHV-2100 (TRPM3) programs.
- Decreased Other Income: Other income, net, dropped to $0.5 million from $4.3 million, primarily due to a $3.6 million non-cash expense related to changes in the fair value of forward contract and derivative liabilities associated with the Knopp Amendment.
- Liquidity Position: Total cash and marketable securities decreased significantly from $495.0 million at the end of Q1 2024 to $322.7 million at the end of Q1 2025, reflecting operational burn and investment maturities.
Guidance, Outlook, and Material Events
- Subsequent Financing Event: On April 28, 2025, the company entered into a Note Purchase Agreement to sell senior secured notes. An initial tranche of $250 million was purchased. Additional tranches of up to $150 million (contingent on FDA approval of troriluzole) and $200 million (for acquisitions) are available. The notes carry revenue interest payments (initially 6.25% of global net sales of troriluzole) and milestone payments.
- Troriluzole (BHV-4157) Status:
- SCA: The FDA accepted the NDA for Spinocerebellar Ataxia (SCA) with priority review; a decision is expected in Q3 2025. The company withdrew the MAA in the EU in March 2025 due to insufficient data for "New Active Substance" status but plans to generate data for a future submission.
- OCD: Two Phase 3 trials are ongoing. Topline data for the first study is expected in the first half of 2025.
- Taldefgrobep Alfa (BHV-2000) Status: The Phase 3 trial in Spinal Muscular Atrophy (SMA) did not meet the primary endpoint at Week 48 but showed clinically meaningful improvements in subgroups. The company plans to engage the FDA in H1 2025 regarding the registrational path. A Phase 2 trial for metabolic disorders (obesity) is planned for initiation in H1 2025.
- BHV-7000 (Kv7) Status: Phase 2/3 trials in focal epilepsy are ongoing. A Phase 2 trial in Major Depressive Disorder (MDD) is expected to report topline results in H2 2025. A Phase 2/3 trial in bipolar disorder failed to meet the primary endpoint in March 2025; no further studies in bipolar are planned.
- Knopp Amendment: The company is obligated to issue approximately 3.6 million shares to Knopp Biosciences by June 30, 2025, as part of the 2025 Additional Consideration.
- Liquidity Outlook: Management expects existing cash, cash equivalents, and marketable securities, combined with the proceeds from the Note Purchase Agreement, to be sufficient to fund operations for at least one year following the issuance date.
Investor Verification Checklist
- Debt Covenants: Review the specific covenants and repayment terms of the $250 million Note Purchase Agreement entered into in April 2025, particularly the revenue interest and "True-Up" payment obligations.
- Troriluzole Regulatory Path: Monitor the FDA decision timeline for the SCA NDA (expected Q3 2025) and the company's strategy for re-engaging the EMA following the MAA withdrawal.
- Cash Burn Rate: Verify the sustainability of the current cash burn rate (~$165 million per quarter) against the new debt proceeds and remaining cash reserves.
- Knopp Share Issuance: Confirm the timing and dilutive impact of the ~3.6 million shares to be issued to Knopp Biosciences in June 2025.
- Clinical Trial Readouts: Track upcoming topline data releases for Troriluzole in OCD (H1 2025) and BHV-7000 in MDD (H2 2025).